Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

Investor Relations

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
June 10, 2019
electroCore Announces Frank R. Amato to Step Down as Chief Executive Officer
BASKING RIDGE, N.J. , June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive
May 29, 2019
electroCore Announces Comprehensive Redeployment and Cost Reduction Plan
Management to host conference call and webcast at 8:30am ET on Thursday, May 30 BASKING RIDGE, N.J. , May 29, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management and the Board of Directors are making
May 14, 2019
electroCore Announces First Quarter 2019 Financial Results
Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities  Company to host conference call and webcast today, May 14 , at 4:30pm ET BASKING RIDGE, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic

Investor Contact

Investor Relations

Hans Vitzthum, LifeSci Advisors
investors@electrocore.com